Tonix reports preliminary 2022 cash $120.2M; burn $98.1M; new $12.5M buyback

Tonix Pharmaceuticals Holding Corp.

Preliminary cash $120.2M at Dec 31, 2022; shares outstanding 76.5M then, 60.9M as of Jan 24, 2023 after repurchases.
Net cash used in operations $98.1M in FY2022 vs $75.6M in FY2021; capex $48.1M vs $35.3M.
Equity proceeds from stock sales $94.5M in 2022 vs $212.4M in 2021.
Since Jan 1, 2023 repurchased 15.7M shares at $0.44-$1.38 under existing $12.5M program.
Board approved new $12.5M share repurchase program funded with available cash.

item 2.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Tonix Pharmaceuticals Holding Corp. reported preliminary financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: preliminary results

Exact text from the filing

Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the year ended December 31, 2022, and certain preliminary financial condition information as of December 31, 2022, as set forth below:

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-23-000543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.